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Abstract
Objective: A significant proportion of adjuvant-treated breast cancer patients experience cognitive decline, challenging
the person’s ability to return to normal activities after treatment. However, not every patient experiences cognitive
problems, and even in patients with impairments, determining clinically important cognitive decline remains
challenging. Our objective was to explore differences in neuropsychological performance following adjuvant
chemotherapy (CT) in patients with breast cancer. Method: We conducted a prospective observational study in an
Oncology Breast Clinic and assessed neuropsychological performance before and after adjuvant CT and in non-CT-
treated women with breast cancer and healthy controls (HCs). Standardised between-group differences and regression-
based change scores were calculated. Results: CT-treated patients (n= 66) performed significantly different from
non-CT-treated patients (n= 39) and HCs (n= 56). There was a significant effect on verbal fluency (p= .0013). CT
performed significantly worse than non-CT and HC [effect size (ES) = .89, p< .001 and ES= .61, p≤ .001, respectively]
and from HCs with regard to proactive interference (ES= .62, p≤ .001). Regression-based scores revealed more severe
cognitive decline in the CT-treated group [24.24% (16/66)] than in the non-CT-treated group [15.20% (6/39)] and
HC group [7.14% (4/56)]. Patients who underwent CT and showed cognitive decline were less educated and older, with
significantly lower baseline scores. Conclusions: CT-treated patients showed more vulnerability on cognitive control and
monitoring than non-CT-treated breast cancer patients and HCs. Older patients with less education and lower baseline
cognitive performance represent a group at risk for cognitive decline following CT. Identification of patients at risk for
decline could improve targeted support and rehabilitation.
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INTRODUCTION
Breast cancer is the most common cancer in women world-
wide with 201 million newly diagnosed cases in 2018
(Bray et al., 2018). Improved treatment results in an approx-
imately 90% disease-free 5-year survival rate, with a sus-
tained rise in long-term survival rates (Noone et al., 2018).
However, patients are often left with a cluster of symptoms
that negatively affect their quality of life (Mitchell, 2007;
Mols, Vingerhoets, Coebergh, & van de Poll-Franse,
2005), thereby influencing their abilities to regain everyday
function and resume vocational and social activities
(De Vries, Den Oudsten, Jacobs, & Roukema, 2014).
Recently, the gradual shift towards patient-reported
outcomes has led to the examination of the impact of cancer
and its treatment on cognitive function, one of the most
common concerns raised by breast cancer survivors, and
an aspect of everyday function that is critical to normal
performance. The term ‘chemobrain’ expresses the burden
experienced by long-term survivors (Schagen et al., 2014).
A considerable number of neuropsychological studies,
supported by animal models and neuroimaging research, sug-
gest cognitive changes in breast cancer survivors, especially
following chemotherapy (CT) (Pomykala, de Ruiter, Deprez,
McDonald, & Silverman, 2013; Seigers, Schagen, Van
Tellingen, & Dietrich, 2013). Although CT is known to be
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cytotoxic to the central nervous system (CNS), prior research
showed that ‘chemobrain’ is a complex phenomenon involv-
ing various factors. Besides chemo-induced toxicity, hormo-
nal changes and inflammatory processes are likely to
contribute to the development of cognitive problems
(Ahles & Saykin, 2007; Nelson & Suls, 2013; Scherling
et al., 2011; Wefel & Schagen, 2012). Also, psychological
distress and fatigue could theoretically result in impaired neu-
roplasticity and impaired cognitive performance (Andreotti,
Root, Ahles, McEwen, & Compas, 2015; Hermelink,
2015). Various candidate mechanisms and a spectrum of
symptoms should be considered when cancer-associated cog-
nitive decline is investigated (Ahles & Saykin, 2007; Ahles &
Hurria, 2018; Andreotti et al., 2015; Hermelink, 2015; Wefel
& Schagen, 2012).
Cognitive domains most commonly affected in breast
cancer patients are attention and processing speed, memory,
and executive function. The latter includes working
memory, cognitive flexibility, and multitasking (Ahles
et al., 2010; Wefel, Saleeba, Buzdar, & Meyers, 2010).
Root, Andreotti, Tsu, Ellmore, and Ahles (2016) argued that
memory is not affected per se, but that an inefficiency in
learning is wrongly perceived by patients as forgetting, pos-
sibly due to inefficiency of attentional processes. Chen, Xu,
Li, Tang, and Wang (2016) showed that following CT,
patients had selective abnormality in alerting and executive
control networks. These findings should be considered
when selecting the cognitive domains to measure in neuro-
psychological assessment.
There are two major challenges in translating clinically
observed symptoms to standardised measures of cognitive
impairment. Firstly, various methods are used to define cog-
nitive decline after cancer at the individual level. Most studies
define impairment as a clinically relevant difference when
comparing patient performance to normative data or perfor-
mances of non-CT-treated patients or healthy controls (HCs).
The boundary between normal and impaired function
depends upon arbitrary thresholds, as it relates to both patient
performance and the normative standard to which it is com-
pared (Schilder et al., 2010; Shilling, Jenkins, & Trapala,
2006). Therefore, it may be interesting to focus on patient per-
formance before therapy, rather than a normative score, since
even in affected patients, post-treatment scores usually stay
within normal boundaries (Jenkins et al., 2006). Moreover,
the degree and nature of cognitive impairment after cancer
are usually assessed in terms of statistical differences in
neuropsychological performance between treatment groups.
By estimating differences in performance, a statistical thresh-
old of significance relates to clinical differences and sample
characteristics, such as group size. Therefore, by comparing
performance between groups, statistical significance should
be accompanied by a normalisation of scores that are typi-
cally observed in the population to provide information on
the severity and impact of cognitive burden (Bernstein,
McCreath, Komeylian, & Rich, 2017; Menning et al., 2016).
Secondly, not all patients following the same treatment
trajectory experience cognitive decline to the same extent,
or even at all. Some patients might even show cognitive
‘improvement’, a common finding after repeated assess-
ments, known as the test–retest effect. Accordingly, average
group scores may appear stable over time, while individual
cases may show marked differences. Thus, even if no mean
difference between treatment groups can be found, it remains
important to examine the possibility of a vulnerable sub-
population of ‘at-risk’ patients (Schagen, Muller, Boogerd,
Mellenbergh, & van Dam, 2006), which requires further
exploration of individual risk factors to optimise rehabilita-
tion programs.
Our goal was to investigate the prevalence of declined per-
formance on neuropsychological tests grouped into the
domains of executive function, verbal memory, and process-
ing speed before and immediately after CT for breast cancer,
compared to performance in non-CT-treated patients and
HCs. We focused on the effect sizes (ESs) of between-group
differences in performance change between baseline and
post-treatment measurements and considered the possibility
of a vulnerable sub-population with a regression-basedmodel
to identify patients with significant cognitive decline.
METHOD
Participants
Patients were recruited at Ghent University Hospital Breast
Clinic between August 2010 and December 2012. All patients
were between 25 and 65 years of age with newly diagnosed
carcinoma of the breast. They were selected for adjuvant
treatment after surgery. One patient group received CT
[5-fluorouracil, epirubicin, and cyclophosphamide (FEC)]
every 21 days for three cycles, followed by three cycles of
docetaxel (D) CT (CT group), and, if necessary, radiotherapy
(RT) and/or endocrine therapy (ET). The other patient group
received RT and/or ET only (non-CT group). The HC group
was recruited from age-matched family and friends of partici-
pants, and women who responded to the invitation to partici-
pate on the website of the hospital. Eligibility screening
excluded women with any history of cancer diagnoses and
treatment, and with psychiatric or neurological disorders, as
well as those not fluent in Dutch. Potential eligible patients
were approached by their healthcare providers. The first author
provided information and obtained informed consent. Of the
196 patients eligible, 111 agreed to participate. The main
reason for refusal was that participation was considered too
burdensome. One patient was excluded because of an inability
to comprehend task instructions (Figure 1).
All participants provided written informed consent. The
Ethical Committee of Ghent University Hospital approved
the protocol (ref: B67020108507).
Procedure
After surgery, but before the start of adjuvant treatment (T1),
each participant completed a standardised neuropsychologi-
cal battery of approximately 1 hour in a set order. For the CT
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group, a second assessment (T2) was performed after the last
cycle of CT, but before the start of RT and/or ET. The non-CT
group was tested within the same time frame, before the start
of adjuvant therapy and 5 months later. The HC group was
tested and retested with a 6-month time interval. A standar-
dised neuropsychological battery of approximately 1 hour
was administered to each patient in a set order.
Neuropsychological Measures
Verbale Leer-en Geheugen Test
The Dutch version of the California Verbal Learning Test
(Verbale Leer-en Geheugen Test – VLGT) is a measure of
verbal memory commonly used to assess both learning and
memory. The presence of a second list B in the VLGT allows
measurement of the effects proactive and retroactive interfer-
ence (RI) on learning and memory (Wohldmann, Healy, &
Bourne, 2008). We retained the total score of list A after five
recall attempts, the distraction list B, the immediate recall of
A, and the delayed recall after 20 minutes, together with pro-
active interference (PI) and RI.
D-KEFS Colour-Word Test
The D-KEFS Colour-Word Test (Delis, Kaplan, & Kramer,
2001) is designed to measure executive control of attention
by involvement of interference of prepotent responses. The
test consists of four trials, the first two consisting of word
reading and colour naming and measuring speed of informa-
tion processing. The third and fourth trials are executive func-
tion tasks.
D-KEFS Trail Making Test
The Trail Making Test of the Delis-Kaplan Executive
Function System (Delis et al., 2001) assesses set-shifting:
the ability to fluently switch between different mental sets.
We included all variables: visual scanning, number sequenc-
ing, letter sequencing as speed of information processing of
the different component skills of this task, and executive
function number-letter switching.
Controlled Oral Word Association Test
Verbal fluency was assessed with the Controlled Oral Word
Association Test (Benton, Hamsher, & Sivan, 1994), a mea-
sure of phonemic and semantic fluency (Miatton, Lannoo, &
Vingerhoets, 2004).
Finally, a Dutch version of the National Adult Reading
Test (NART [Nelson & Willison, 1991]; DART [Schmand,
Lindeboom, & Harskamp, 1992]) was administered to obtain
an estimation of intelligence.
Statistical Analysis
SPSS Statistics for Windows (version 25.0, IBM Corp.,
Armonk, NY, USA) was used for descriptive analyses. All
other analyses were performed in R (Version 3.0.2, R
Foundation for Statistical Computing, Vienna, Austria).
Standardisation of the data set
For interpretation purposes, raw scores of neuropsychologi-
cal tests were converted into standardised scores based on the
mean and standard deviation (SD) of the HC group at T1.
Hence, for the HC group at T1, each parameter was distrib-
uted with zero mean and SD equal to 1.
Group differences
T2 scores were also standardised based on the mean and the
SD of the HC group on T1. This allowed us to then calculate
differences between T2 and T1 scores which were based on the
same standardisation, thus providing a more direct link with
raw differences (as opposed to, for example, T2 corrected
for T1). Paired samples t-tests were conducted to compare
performance in all neuropsychological measures between
HCs and the two patient groups. ESs were calculated as
Cohen’s d (mean paired differences/SD paired differences).
We calculated the difference score (T2minus T1) and assessed
significant differences between the groups. P-values indicated
group as a significant predictor. Applying multi-comparison
Bonferroni correction, we deemed differences with p< .001
as statistically significant. For each test value, groups were
compared, and we calculated ES, confidence interval (CI),
and p-value. Generally, an ES of .8 or more is considered a
large effect, an ES of .5 is considered moderate, and an ES
of .2 is considered a small effect.
Regression-Based Change
As previously mentioned, it is important to compare group
differences and to determine which subgroups of patients
show relevant decline. To detect which subgroup of patients
show clinically relevant decline, we used RBC scores
(McSweeny, Naugle, Chelune, & Lüders, 1993), which origi-
nate from differences in initial baseline scores, considering
relevant demographic variables that could influence change
in a test–retest situation.
For the different test variables, we calculated optimal
regression coefficients by regressing the retest scores for
Potentially eligible 
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Fig. 1. Flowchart of participants. CT, chemotherapy; mo, months.
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the HC group against their prior scores (Supplementary
Material A). Potential contributing factors, such as age,
intelligence, education, and fatigue, were added to the equa-
tion, together with sleep quality and menopausal status
(Henneghan, Carter, Stuifbergan, Parmelee, & Kesler,
2018; Lord, Buss, Lupien, & Pruessner, 2008). Beginning
with performance on T1, the predicting variables were incre-
mentally added until the best model was achieved. T1 score
and age were important contributing factors. Following
these regression models (Supplementary Material B), we
calculated optimal regression coefficients and predicted
T2 scores for patients in the CT and non-CT groups.
To determine whether a patient’s retest performance sig-
nificantly deviated from normal expectations, we compared
the observed retest score with the regression-predicted retest
score and divided the difference by the mean square error.
We obtained standardised difference scores that represent
to what extent the actual score on T2 deviated from what
would be expected based on the T1 score and the change
occurring in the HC group. The standardisation of the T2
scores based on the mean and SD of HCs at T1 distributes
solely for ability (þ error). However, we argue that degree
of change expected in controls is modelled for using the
linear regression models. These are oriented towards
estimating how much a patient in the control group, given
a certain starting ability and demographic factors, should
be expected to show practice effects. By contrasting the
standardised T2 scores of the experimental conditions
against the expected scores based on these models, we thus
investigate these groups relative to both ability and practice
effects in the control group.
To delineate which participants deviated significantly from
their expected T2 scores (and can thus be said to have experi-
enced cognitive decline), it is necessary to set a cut-off point to
the RBC scores. The heterogeneity of definitions of impair-
ment makes such conclusions somewhat arbitrary. Given the
large differences that exist in the determination of a threshold
in previous papers (Schilder et al., 2010), we have decided to
include a table detailing the prevalence of ‘declined’ subgroups
in the different conditions for several thresholds. Even though
we decided to uphold the standard of choosing 2.5 SD, we
agree that placing the boundary at −2.5 SD is a subjective
decision (which is why we chose to also include what the
‘declined’ group would look like following −1.5 SD and
−2 SD). We applied the reasoning that if the ‘significantly
worse performing’ group was based on a boundary less than
−2.5 SD, this would not follow the restrictions typically placed
on determining outliers within a distribution. It might be
relevant for other papers to better compare these subgroups
to their own threshold selection (Schagen et al., 2006).
RESULTS
Demographic and Clinical Characteristics
Demographic and clinical characteristics of both patient
groups and HCs are presented in Table 1. From the final
sample of 110 patients that completed T1, 69 received adju-
vant CT (CT group). Forty-one patients received RT and/or
ET (non-CT group). Ninety-six percent of patients in the
CT group received the combination of FEC/D. All but one
patient (97.6%) in the non-CT group received adjuvant ET,
compared to 77% in the CT group. The average age of all
women was 49.1 years. Patients in the non-CT group were
significantly older, and adjuvant CT was associated with
higher cancer stage. Nearly 90% of patients in the non-CT
group had a pT1 tumour, while 50.7% of those in the CT
group had pT2 breast cancer. Thirty-nine patients in the
CT group (56.4%) and 19.5% in the non-CT group had
positive lymph nodes. Before treatment, 35%, 54%, and
43% of patients in the CT, non-CT, and HC groups, respec-
tively, were postmenopausal. No significant differences in
education and estimated intelligence quotient (IQ) were
found. Three patients in the CT group and two in the
non-CT group dropped out at T2. In the HC group, 4 of 60
participants dropped out by T2. Thus, complete data were
obtained from 105 patients and 56 HCs.
Group Differences in Cognitive Change
Patient groups and controls did not differ in most neuro-
psychological tests (Supplementary Materials C and D),
but a significant difference was found for verbal fluency-
letters (p= .0013), with a large ES between the CT and
non-CT groups (ES= .89, p≤ .001) and moderate ESs on
verbal fluency-letters between the CT and HC groups
(ES= .61, p= .0011) and for VLGT PI between the CT
and HC groups (ES= .62, p≤ .001). Thus, the CT group
showed significant decline on letter fluency and the PI task
of the VLGT compared to the other groups.
Cognitive decline versus no cognitive decline
As explained earlier, we systematically selected subgroups of
patients with standardised difference scores of −2.5 SD.
Using the −2.5 points threshold, the percentages of subjects
with cognitive decline were 24.24% (16/66) in the CT group,
15.20% (6/39) in the non-CT group, and 7.14% (4/56) in the
HC group (Supplementary Material E). Therefore, the pro-
portion of participants performing lower than expected
between T1 and T2 significantly differed between the groups
(χ2=6.973, p= .030608).
Furthermore, to link this relative decline in cognitive per-
formance to actual differences in neuropsychological mea-
sures, we used independent group comparisons for raw
scores at T2; observing that the subgroup of participants with
cognitive decline had significantly lower raw scores at T2
than those without cognitive decline, especially in the CT
group (SupplementaryMaterial F). For all analyses, a p-value
<.01 was considered statistically significant. The CT group
with cognitive decline scored significantly lower than the
group without cognitive decline on the VLGT total recall
(p= .0007), short delay recall (p= .0029), long delay recall
4 W. Schrauwen et al.
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(p= .009), D-KEFS visual scanning (p= .002), D-KEFS
letter (p= .0022), D-KEFS switching (p= .001), D-KEFS
word reading (p= .003), D-KEFS inhibition (p= .00043),
D-KEFS inhibition/switching (p= .0006), and verbal flu-
ency-letter (p= .0001) tests. In the non-CT group, there were
only significant differences on verbal fluency-animals
(p= .0065) and profession (p= .0018). No statistically
significant difference (p< .01) was retained between any
measures in HCs.
When relating the raw T2 scores to the T1 scores for the
groups with and without cognitive decline, results indicated
that the group with cognitive decline typically consisted of
those who had already lower performance at T1, which
remained within the normal range. No statistically significant
differences (p< .001) between any measures in the non-CT
and HC groups with and without cognitive decline were
retained at T1. In the CT group, the group that showed ‘later
decline’ performed significantly worse on T1 than the group
that did not show later decline in the VLGT total recall
(p= .0015), short delay recall (p= .0088), D-KEFS TM
numbers (p= .0033) D-KEFS TM letter (p= .0029), and
D-KEFS TM switching (p= .0058) tests. Figure 2 depicts
the subtle deterioration of the subgroup already scoring
lower at T1.
Finally, patients with and without cognitive decline
differed in several features, as summarised in Table 2.
Participants with significant cognitive decline had a lower
level of education overall, but this was only significant in
the CT group. Patients with cognitive decline were also sig-
nificantly older in the CT group. Participants with cognitive
decline showed lower estimated intelligence, but this was
only significant in the non-CT group.
DISCUSSION
The primary focus of this study was to investigate the preva-
lence of cognitive decline in women with breast cancer
immediately after CT, compared to the performance of
non-CT treated patients and HCs. Following concerns of pre-
vious studies, we attempted to study cognitive decline not
through significant deviations from norm scores; however,
we focused on ESs in between-group changes using scores
standardised based on HC performance. Furthermore, we
explored the relevance of discerning an ‘at-risk’ subgroup,
using standardised RBC scores to identify patients with dys-
functional evolutions in their cognitive performance. Thus,
we adhered to recent methodological recommendations to
evaluate psychometric changes in longitudinal studies
(Andreotti et al., 2016).
Group Level
At the group level, results showed several between-group
differences. Both CT and non-CT patient groups showed less
resistance to PI at T2. In contrast to the findings by Root et al.
(2016), performance in the VLGT distraction list opposing











Characteristics Mean or count SD Mean or count SD Mean or count SD F-statistic p
Age at baseline years (range) 46.7 (27–64) 9.7 53.1 (44–65) 5.6 47.9 (25–64) 10.6 7.643 .001
pTNM classification <.001*
T1 21 (30.4%) 36 (87.8%) NA
T2 35 (50.7%) 5 (12.2%) NA
T3 12 (17.4%) NA NA
T4 1 (1.4%) NA NA
Positive lymph nodes 39 (56.4%) 8 (17.1%) NA <.001*
Menopausal status .497 .609
Premenopausal 45 (65.2) 19 (46.3%) 32 (57.1%)
Postmenopausal 24 (34.8) 22 (53.7%) 22 (42.9%)
Surgical treatment .001*
Lumpectomy 30 (43.5%) 33 (80.5%) NA
Mastectomy 35 (50.6%) 8 (19.5%) NA
Radiotherapy
y 65 (94.2%) 36 (87.8%) NA .239
n 4 (5.8%) 5 (12.2%)
Hormonal therapy
y 53 (76.8%) 40 (97.6%) NA .004*
n 16 (23.2%) 1 (2.4%)
Education years 13.7 2.9 13.5 2.6 14.5 2 1.968 .114
Estimated IQ 111.4 10.2 112.8 11.4 116.5 10.2 1.492 .228
ANOVA, analysis of variance; IQ, intelligence quotient; NA, not applicable; SD, standard deviation; pTNM, classification of malignant tumours; y-n: yes – no.
*Disease variables between the two patient groups were assessed with the Mann–Whitney U Test; significance values are reported.
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the first encoding of list A seemed more difficult in both
groups. The shifting of attention while inhibiting learned
material caused problems for patients, whereas HCs showed
improvement; therefore, patients were less able to inhibit pre-
viously learned – distracting – information. These results are
comparable with data published by Andryszak in a recent
study on verbal memory in CT-treated breast cancer patients
compared to HCs (Andryszak, Wiłkość, Żurawski, &
Izdebski, 2018). The presence of list B did not otherwise
inhibit retrieval of previously memorised material (RI).
Comparing CT-treated patients with both non-CT and HC
groups, we found large ESs for letter fluency [CT vs. Non-
CT (ES= .89); CT vs. HC (ES= .61)]. In the letter fluency
task, patients must maintain instructions in working memory
and suppress semantically related words while adapting novel
search strategies; this measures verbal and executive control
ability. Prior research suggests the effects of CT on specific
domains of executive functioning. These findings suggest
that CT-treated patients are vulnerable to cognitive control
and monitoring (Chen et al., 2014; Yao, Bernstein, &
Rich, 2017). Deficits in executive functioning may not have
Fig. 2. Visual presentation of declined and non-declined T1 and T2. The prediction line consists of the mean of the total CT group at T1 and
the predicted score at T2, the latter on the basis of the expected evolution of the CT group, given their basic score, age, education, and other
factors in this study, as well as the evolution of the HC group.
Table 2. Comparison of features in patients with and without
cognitive decline
Group Decline No decline p (t test)
Education years HC 13.2 14.8
Non-CT 11 14 0.068
CT 10.8 14.6 0.0006*
Sleep quality HC 7.5 7.2 0.414
Non-CT 7 7,1 0.732
CT 7 7 0.88
IQ HC 112 117 0.339
Non-CT 100.5 115 0.0038*
CT 106 113 0.089
Age HC 48.2 47.9 0.9634
Non-CT 52 53.2 0.837
CT 53.5 44.6 0.00037*
Days since surgery HC
Non-CT 20 28.5 0.0395
CT 19.4 19.4 0.9934
CT, chemotherapy; HC, healthy control; IQ, intelligence quotient.
*p< 0.001.
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been reflected in the Colour-Word and Trail making task
because of a lack of sensitivity in these tests. Moreover, in
contrast to these tests, the letter fluency task requires greater
effort and a more active strategic search. Regardless of the
observation of significant differences on some measures,
no other significant group differences were found globally.
Despite the reduced performance that was observed in the
CT group, the non-CT group also received cancer treatment,
such as RT, hormonal therapy, and the additional effects of
psychological factors and fatigue (Ahles & Root, 2018;
Andreotti et al., 2015; Boele, Schilder, de Roode, Deijen,
& Schagen, 2015; Menning et al., 2015) with a potential neg-
ative impact. Our findings agree with recent meta-analyses
that emphasize the subtlety of cognitive dysfunction, but
deviate somewhat from the findings that cognitive impair-
ments in breast cancer patients occur independently of CT
(Bernstein et al., 2017; Ono et al., 2015).
Individual Level
We aimed to determine whether a subgroup of patients with
cognitive decline could be identified using RBC scores to
predict individual performance. We observed a larger sub-
group with severe cognitive decline among CT-treated
patients, compared to the other groups. Twenty-four percent
of patients in the CT group showed scores 2.5 points lower
than expected in more than one test at T2, compared to
15% and 7% of those in the non-CT and HC groups, respec-
tively. Lower education level and older age were significant
predictors of cognitive decline in the CT group. An associa-
tion between decline and age could not be found in the other
groups. Other researchers demonstrated associations among
cognitive performance, age, and years of education, with a
larger effect in CT-treated patients than in non-CT-treated
patients (Ahles & Hurria, 2018; Tager et al., 2010).
Dichotomisation of patients into those with and without
cognitive decline could have concealed the fact that all
CT-treated patients experience negative cognitive effects;
however, only patients with lower IQ and education were
unable to maintain task performance, whereas younger
patients with higher education were more resilient to decline.
Study Limitations
This study had several limitations. First, a number of patients
declined to participate, mainly because of the burden of the
given diagnosis at that time. Second, all participants were
white and Flemish, the majority of whom were highly edu-
cated and financially stable, limiting the external validity
of the findings. Given the small number of included partici-
pants, a further limitation is that the study may have been
underpowered to identify predictors of cognitive decline
within subgroups. Fourth, we evaluated the acute, short-term
effects of CT; we did not include the analysis of long-term
cognitive performance of the patient groups. And finally,
in this paper, we did not include an assessment of perceived
cognitive decline nor of any other possible contributing
psychological factors. Since mechanisms that cause cognitive
decline in breast cancer patients are likely to be multi-
factorial, these factors may increase vulnerability to cognitive
deterioration and should be considered for future research.
Clinical Implications
The results corroborate the hypothesis that CT is an important
factor in cognitive decline in breast cancer patients. The find-
ings of this study can alert healthcare professionals of the
need to identify and support breast cancer patients with poten-
tial decline, thereby facilitating targeted rehabilitation after
treatment for breast cancer. The findings also emphasise that
healthcare professionals and researchers should carefully use
terms such as ‘impairment’ and ‘dysfunction’. There is a need
to agree on a definition of cognitive decline and standardise
the methodology for accurate assessment, thus allowing
comparison of studies regarding the prevalence and nature
of cognitive dysfunction in patients who have undergone
treatment for cancer.
Future Studies
The possibility that psychological factors increase vulnerabil-
ity for cognitive decline after cancer treatment remains con-
troversial (Vearncombe & Pachana, 2009). Core executive
functions, such as task-switching and inhibition, are essential
for task performance, but also serve self-regulatory abilities.
Berman et al. (2014) showed that pre-treatment worry was
associated with cognitive impairment; other research has
linked the lack of cognitive control to a higher tendency to
ruminate (De Lissnyder, Koster, Derakshan, & De Raedt,
2010). Further research is needed to determine whether cog-
nitive function and perseverative cognitions share common
factors.
Finally, the tendency to objectify cognitive complaints
after cancer resulted in a neglect of subjective experience.
Qualitative studies addressing the phenomenology of cogni-
tive difficulties are limited but can only enrich and comple-
ment existing research.
To conclude, our findings revealed no significant global
difference in performance between CT- and non-CT-treated
participants, aside from cognitive control and monitoring
frailty in verbal fluency letters and PI performance.
Seventy-five percent of patients in the CT group continued
to perform normally; however, compared with HCs, a signifi-
cantly larger subgroup of participants with cognitive decline
could be discerned. In particular, those who already per-
formed more weakly before adjuvant treatment and with
lower education levels and higher age were prone to further
deterioration in performance; they constituted a vulnerable
group. We should, however, not disregard the fact that neuro-
psychological assessment may not be sufficiently sensitive
to capture the complexity of cognitive problems in cancer
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survivors and that patient-reported outcomes should be incor-
porated into such assessments.
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